Synthetic Cannabinoid Withdrawal Included Psychosis, Seizures, and Rhabdomyolysis
A systematic review of 11 case reports found synthetic cannabinoid withdrawal produced more severe symptoms than natural cannabis withdrawal, including psychosis (82% of cases), seizures (45%), and rhabdomyolysis, typically emerging within 24-48 hours.
Quick Facts
What This Study Found
Most frequent withdrawal symptoms were psychosis (n=9, 82%), agitation/irritability (n=8, 73%), nausea/vomiting (n=6, 55%), seizures (n=5, 45%), tachycardia (n=4, 36%), and insomnia (n=3, 27%). Rarer effects included delirium, rhabdomyolysis, and hallucinations. Symptoms emerged within 24-48 hours in 62% of cases and resolved within 1 week. Cases were predominantly male (82%), mean age 28.
Key Numbers
11 case reports. 82% male. Mean age 28.08 (SD 7.78). Psychosis: 82%. Agitation: 73%. Nausea/vomiting: 55%. Seizures: 45%. Tachycardia: 36%. Insomnia: 27%. Onset: 24-48 hours (62%). Resolution: within 1 week. Average CARE checklist score: 8/13.
How They Did This
Systematic review of PubMed/Medline, Scopus, EMBASE, and PsycINFO from inception to March 2025 for case reports describing synthetic cannabinoid withdrawal. 11 eligible case reports identified. Quality assessed using CARE guidelines checklist (average 8/13 items).
Why This Research Matters
Synthetic cannabinoids are often marketed as legal alternatives to cannabis, but their withdrawal profile is dramatically different and more dangerous. Psychosis in 82% of cases and seizures in 45% highlight the need for clinical awareness and prompt medical management.
The Bigger Picture
Natural cannabis withdrawal is generally mild (irritability, insomnia, decreased appetite). Synthetic cannabinoid withdrawal can be life-threatening. This stark difference reflects the much higher potency and different pharmacology of synthetic cannabinoids, which are full agonists at CB1 receptors compared to cannabis's partial agonism.
What This Study Doesn't Tell Us
Only 11 case reports available worldwide, reflecting both rarity and underreporting. Case reports are the lowest level of evidence. No standardized withdrawal assessment tools were used across cases. Variable quality of reporting. Cannot determine incidence of withdrawal among synthetic cannabinoid users.
Questions This Raises
- ?What percentage of regular synthetic cannabinoid users experience withdrawal symptoms
- ?Whether benzodiazepine or antipsychotic protocols are more effective for managing synthetic cannabinoid withdrawal
Trust & Context
- Key Stat:
- Evidence Grade:
- Systematic search with quality assessment, but limited to case reports (lowest evidence level) with only 11 cases worldwide, likely underrepresenting the true scope.
- Study Age:
- Published 2025, searching through March 2025.
- Original Title:
- Synthetic Cannabinoid Withdrawal: A Systematic Review of Case Reports.
- Published In:
- European addiction research, 31(4), 274-285 (2025)
- Authors:
- Sharma, Rishi, Weinstein, Aviv(5)
- Database ID:
- RTHC-07635
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
How is synthetic cannabinoid withdrawal different from marijuana withdrawal?
Natural cannabis withdrawal typically causes mild irritability, insomnia, and appetite changes. Synthetic cannabinoid withdrawal can cause psychosis, seizures, rhabdomyolysis, and delirium, often requiring emergency medical care. The difference reflects synthetic cannabinoids' much higher potency at brain receptors.
Why are synthetic cannabinoids more dangerous?
Unlike THC (a partial agonist), synthetic cannabinoids are full agonists at CB1 receptors with much higher binding affinity. This means they cause stronger receptor activation, leading to more severe dependence and more dangerous withdrawal when stopped abruptly.
Read More on RethinkTHC
- THC-purity-potency-label-meaning
- dab-concentrate-addiction-withdrawal
- delta-8-addiction-withdrawal
- edible-addiction-withdrawal-different
- edibles-psychosis-emergency-room
- healthiest-way-to-consume-cannabis
- how-cannabis-products-made-concentrates-edibles
- laced-weed-fentanyl-contaminated-vape
- legal-weed-vs-street-weed-quality-safety
- quitting-dabs-withdrawal
- quitting-edibles-withdrawal
- sativa-vs-indica-difference-myth
- weed-potency-withdrawal
Cite This Study
https://rethinkthc.com/research/RTHC-07635APA
Sharma, Rishi; Weinstein, Aviv. (2025). Synthetic Cannabinoid Withdrawal: A Systematic Review of Case Reports.. European addiction research, 31(4), 274-285. https://doi.org/10.1159/000546633
MLA
Sharma, Rishi, et al. "Synthetic Cannabinoid Withdrawal: A Systematic Review of Case Reports.." European addiction research, 2025. https://doi.org/10.1159/000546633
RethinkTHC
RethinkTHC Research Database. "Synthetic Cannabinoid Withdrawal: A Systematic Review of Cas..." RTHC-07635. Retrieved from https://rethinkthc.com/research/sharma-2025-synthetic-cannabinoid-withdrawal-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.